Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Epilepsy, which afflicts approximately 4.9 million people in the G7 according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, as a path to differentiation, most developers are targeting underserved, orphan pediatric epilepsy populations, or they are developing reformulations of existing products as rescue therapies. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Emerging therapies: Phase II: 9 drugs; Phase III/preregistration: 8 drugs; coverage of select preclinical and Phase I products.
Market forecast features: Patient-based market forecast extending through 2028, segmented by brands/generics.
Key companies: Aquestive Therapeutics, Eisai, GlaxoSmithKline, GW Pharmaceuticals, Insys Therapeutics, Lundbeck, Marinus Pharmaceuticals, Neurelis, Pfizer, Sanofi, SK Biopharmaceuticals, Sunovion, Supernus, UCB, Upsher-Smith, Zogenix.
Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), AQST-120 (clobazam oral film), Epidiolex (plant-derived CBD), synthetic CBD, ZX-008 (fenfluramine), YKP-3089 (cenobamate), padsevonil, AQST-203 (buccal diazepam), NRL-1 (intranasal diazepam), USL-261 (intranasal midazolam).
Already a Client? Log in to access this report.
Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.
"Niyati Khetarpal is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;